The safety profile will be a key factor in discussions with regulators regarding Merck & Co.’s (MRK) new drug for the treatment of diabetic macular edema, Freedom Broker analysts believe. Previously, the experts maintained a “Hold” rating and a $125 target price: with the shares priced at $129.40 at the time, this implied downside potential of about 3.4%.

What Merck does
Merck is one of the world’s largest pharmaceutical companies. It develops prescription medicines, vaccines, and animal health products. The main source of revenue remains the cancer drug Keytruda, which generates about half of sales.
The company is also developing new medicines, including for the treatment of eye diseases. Remigromig is intended for the treatment of diabetic macular edema— a diabetes complication in which fluid accumulation in the central part of the retina impairs vision.
Efficacy confirmed, but safety questions remain
In a Phase IIb/III study, remigromig was non-inferior in efficacy to ranibizumab, the drug it was compared against. However, complications occurred more frequently with the experimental medicine.
Freedom analysts highlight the safety profile as the key issue for further discussions with regulators. It includes the nature and frequency of adverse reactions during treatment. Thus, when evaluating the new drug, not only the therapy outcomes matter, but also the complications associated with it.
Revenue is growing, reliance on Keytruda remains
In Q2 2026, Merck’s revenue rose 5% year over year to $16.6 billion. Sales of the Keytruda cancer-drug franchise increased 5% to $8.37 billion, including $463 million in revenue from the subcutaneous form of the drug.
New products grew faster: sales of the pulmonary hypertension drug WINREVAIR jumped 75% to $588 million, the cancer drug WELIREG rose 67% to $271 million. Sales of the pneumococcal vaccine CAPVAXIVE increased 42% and reached $184 million.
In an August assessment, Freedom Broker noted that new drugs confirm the development of the company’s portfolio, but are not yet able to offset the future loss of exclusivity for Keytruda. After patent protection expires, competition from other manufacturers may intensify.
What underpinned the “Hold” recommendation
Following the quarterly results, Merck raised its 2026 revenue guidance to $66.3–67.3 billion from $65.8–67 billion. Adjusted EPS guidance was set at $2.66–2.76, reflecting significant expenses related to deals with Cidara and Terns Pharmaceuticals.
Freedom analysts then maintained a “Hold” recommendation. In addition to dependence on Keytruda, they highlighted uncertainty around the recovery of international sales of the Gardasil vaccine, primarily in China. In Q2, sales of this product increased 4% to $1.17 billion.
The October assessment of remigromig results addresses its efficacy and safety. A new target price for the shares or a change in the recommendation is not provided in the review dated October 12.
This is not an individual investment recommendation.